Vertex Pharmaceuticals (VRTX) Tax Provisions (2011 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Tax Provisions of $221.5 million for Q1 2026, up 163.38% year-over-year from $84.1 million in Q1 2025, and up 58.33% on a QoQ basis from $139.9 million in Q4 2025.
Vertex Pharmaceuticals (VRTX) Tax Provisions (2011 - 2026) Analysis & Trends
Vertex Pharmaceuticals (VRTX) has reported Tax Provisions for 16 consecutive years, with $221.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Tax Provisions rose 163.38% year-over-year to $221.5 million; the TTM figure through Mar 2026 stood at $827.4 million (up 20.14% YoY), while the FY2025 annual figure was $690.0 million, down 12.0% from the prior year.
- Tax Provisions came in at $221.5 million for Q1 2026 at Vertex Pharmaceuticals, up from $139.9 million in the prior quarter.
- The five-year high for Tax Provisions was $257.9 million in Q4 2022, with the low at $84.1 million in Q1 2025.
- Average Tax Provisions over 5 years is $198.0 million, with a median of $202.4 million recorded in 2024.
- Across the five-year window, Tax Provisions surged 292.36% in 2022 and slumped 53.15% in 2025, its largest moves.
- Year by year, Tax Provisions stood at $257.9 million in 2022, then plunged by 30.67% to $178.8 million in 2023, then gained by 25.0% to $223.5 million in 2024, then plunged by 37.4% to $139.9 million in 2025, then soared by 58.33% to $221.5 million in 2026.
- According to Business Quant data, Tax Provisions over the past three periods registered $221.5 million, $139.9 million, and $215.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Genmab A | 276,399.99 Bn | 276,398.47 Bn | 831.00 Mn | - |
| 2 | Akari Therapeutics | 1,217.26 Bn | 1,217.26 Bn | - | -859,000.00 |
| 3 | BeOne Medicines | 419.38 Bn | 414.59 Bn | 1.35 Bn | 31.86 Mn |
| 4 | Vertex Pharmaceuticals | 126.54 Bn | 119.30 Bn | 2.59 Bn | 221.50 Mn |
| 5 | Pharming | 110.17 Bn | 110.12 Bn | 65.80 Mn | -459,000.00 |
| 6 | Regeneron Pharmaceuticals | 64.97 Bn | 56.22 Bn | 3.31 Bn | 104.00 Mn |
| 7 | Argenx Se | 56.44 Bn | 56.44 Bn | 1.18 Bn | 60.00 Mn |
| 8 | Alnylam Pharmaceuticals | 40.09 Bn | 37.08 Bn | 959.66 Mn | 15.66 Mn |
| 9 | Revolution Medicines | 37.15 Bn | 37.15 Bn | - | - |
| 10 | Moderna | 28.64 Bn | 23.43 Bn | -566.00 Mn | 9.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 221.50 Mn |
| Dec 31, 2025 | 139.90 Mn |
| Sep 30, 2025 | 215.90 Mn |
| Jun 30, 2025 | 250.10 Mn |
| Mar 31, 2025 | 84.10 Mn |
| Dec 31, 2024 | 223.50 Mn |
| Sep 30, 2024 | 178.70 Mn |
| Jun 30, 2024 | 202.40 Mn |
| Mar 31, 2024 | 179.50 Mn |
| Dec 31, 2023 | 178.80 Mn |
| Sep 30, 2023 | 143.90 Mn |
| Jun 30, 2023 | 245.80 Mn |
| Mar 31, 2023 | 191.70 Mn |
| Dec 31, 2022 | 257.90 Mn |
| Sep 30, 2022 | 245.90 Mn |
| Jun 30, 2022 | 213.90 Mn |
| Mar 31, 2022 | 192.70 Mn |
| Dec 31, 2021 | 100.80 Mn |
| Sep 30, 2021 | 230.90 Mn |
| Jun 30, 2021 | -111.20 Mn |